These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 16167051)

  • 1. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC; Corless CL
    J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
    Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
    Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
    Samelis GF; Ekmektzoglou KA; Zografos GC
    Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal stromal tumors.
    von Mehren M; Watson JC
    Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
    Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC;
    Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
    Papaetis GS; Syrigos KN
    Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.